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ABSTRACT
Tumor Endothelial Marker-1 (TEM1/CD248) is a tumor vascular marker with 
high therapeutic and diagnostic potentials. Immuno-imaging with TEM1-specific 
antibodies can help to detect cancerous lesions, monitor tumor responses, and select 
patients that are most likely to benefit from TEM1-targeted therapies. In particular, 
near infrared(NIR) optical imaging with biomarker-specific antibodies can provide 
real-time, tomographic information without exposing the subjects to radioactivity. 
To maximize the theranostic potential of TEM1, we developed a panel of all human, 
multivalent Fc-fusion proteins based on a previously identified single chain antibody 
(scFv78) that recognizes both human and mouse TEM1. By characterizing avidity, 
stability, and pharmacokinectics, we identified one fusion protein, 78Fc, with desirable 
characteristics for immuno-imaging applications. The biodistribution of radiolabeled 
78Fc showed that this antibody had minimal binding to normal organs, which have 
low expression of TEM1. Next, we developed a 78Fc-based tracer and tested its 
performance in different TEM1-expressing mouse models. The NIR imaging and 
tomography results suggest that the 78Fc-NIR tracer performs well in distinguishing 
mouse- or human-TEM1 expressing tumor grafts from normal organs and control grafts 
in vivo. From these results we conclude that further development and optimization 
of 78Fc as a TEM1-targeted imaging agent for use in clinical settings is warranted.
INTRODUCTION
Antibody-based diagnostic and therapeutic strategies 
are entering center stage as cancer treatment options. While 
intact monoclonal immunoglobulins (mAbs) constitute 
the majority of US Food and Drug Administration (FDA) 
approved antibody-based therapeutics, minimal fragment 
derivatives, such as the single chain Fv (scFv) that 
target tumors have demonstrated promising therapeutic 
potential in recent clinical trials (reviewed here [1]). 
Rapid advances, both in the screening of human-derived 
antibody libraries, and in the engineering of scFv-based 
protein derivatives now provide great opportunities for 
developing highly specific multivalent antibody fragments 
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tailored to meet the stringent functional demands required 
for various clinical applications. 
Immuno-imaging with tumor biomarker-specific 
antibodies is a rapidly developing research area. Immuno-
imaging can provide vital information on tumor stages 
and tumor response without invasive treatments, and 
it can also help to screen for patients that are likely to 
benefit from specific targeted therapies. In fact, several 
124I- or 89Zr-labeled mAb radiopharmaceuticals have 
been approved by FDA in immuno-PET (positron 
emission tomography) and SPECT (single-photon 
emission computed tomography) imaging applications 
[2]. Recently, optical imaging has attracted increasing 
attention as an alternative imaging approach for cancer. 
Immuno-optical imaging requires no radioactivity, is able 
to acquire real-time intraoperative imaging information, 
and can be used for both two-dimensional imaging and 
three-dimensional tissue reconstruction [3]. For example, 
intraoperative detection of breast cancer [4] and lymph 
node mapping [5-9] within clinical settings is regularly 
performed using optical imaging with indocyanine green 
(ICG). Hence, due to its non-invasive and non-radioactive 
advantages, optical imaging using tumor biomarker-
specific antibodies is particularly well suited to serve as 
a complimentary imaging technique to PET/SPECT. In 
particular, by exploiting the unique properties of light 
at near infrared (NIR) wavelengths, the “NIR optical 
biopsy”, in combination with endoscopy or camera, allows 
direct visualization of marker expression in live tissues in 
vivo, thus circumventing the need for histo- or cytological 
staining of specimens taken from target tissues. In 
addition, as optical imaging is less expensive and imposes 
no radioactive burden on the subject of study, it can be 
especially attractive as a tool for antibody development 
and optimization. 
The success of immuno-optical imaging relies 
critically on the identification of robust biomarkers and 
the subsequent development of antibodies with the 
appropriate stability and pharmacokinetic profiles for 
imaging applications. In recent years, several markers 
associated with the tumor vasculature (TVM) have 
received considerable attention as therapeutic targets [10-
15]. Key drivers have been their low rates of mutation 
relative to cancer cells [16, 17], direct accessibility 
to exogenous agents via the circulation, and their 
compelling association with angiogenic processes shown 
to be essential for tumor disease progression. Blockade 
of the latter is clearly correlated with tumor regression 
and is an established anti-cancer strategy [18, 19]. To 
this end, multiple lines of evidence have suggested that 
Tumor Endothelial Marker 1 (TEM1/endosialin/CD248) 
is a promising TVM target: TEM1 is implicated in 
neo-angiogenesis [20, 21], vascular cell adhesion and 
migration [22, 23], and tumor progression [24]; in breast 
cancer, TEM1 overexpression correlates with lymph node 
metastasis, recurrence and death [25]; in ovarian cancer, 
increased TEM1 expression was found in the endothelial 
cells and vasculature-associated leukocytes in the tumor 
microenvironment [26]; the expression levels of TEM1 are 
considerably higher in the tumor vasculatures of various 
cancers [13, 20, 21, 27-31] but below the detection limit 
[20, 21] in normal adult tissues; and TEM1 knockout did 
not impair any normal biological processes in mice [32]. 
In addition to its vascular expression in ovarian and other 
carcinomas, TEM1 has been shown to be upregulated 
in the tumor cells of sarcomas [33, 34]. Further, a 
humanized mouse monoclonal antibody targeting TEM1, 
MORAb-004 [21], is currently undergoing phase-1 clinical 
trials for the treatment of patients with various cancers. 
We previously reported the first immuno-PET imaging 
study in preclinical animal models using this mAb [35, 
36]. However, despite the obvious therapeutic interest, 
suitable imaging tools to explore the potential of TEM1 
as a diagnostic marker have to-date not been reported 
otherwise.
We have recently isolated a TEM1-specific fully-
human scFv, scFv78, which was shown to bind with 
high affinity to both human and mouse TEM1 [37], and 
thus to have relevance as a test molecule in preclinical 
models. It is widely considered, however, that the 
functional efficacy of the scFv format is often limited due 
to its small size and monovalency (reviewed here [1]). We 
have sought to exploit the TEM1 recognition potential 
of scFv78 for immuno-imaging applications by fusing 
it to an immunoglobulin Fc domain. Fc-fusion proteins 
often demonstrate a number of beneficial biological 
and pharmacological characteristics: firstly, the plasma 
half-life of the Fc-containing fusion proteins are often 
significantly improved due to slower renal clearance 
and enhanced interaction with salvage Fc receptors [38]; 
secondly, the presence of an Fc domain allows easy 
purification of the fusion protein by protein-G/A affinity 
chromatography [39]; finally, the Fc fragment is dimeric 
in the native state which serves to increase the avidity of 
the scFv fusion partner, potentially improving potency 
(sensitivity) and performance in demanding applications, 
such as those encountered in the clinic. Currently, several 
Fc-fusion proteins have undergone clinical testing and 
have demonstrated favorable pharmacokinetics, half-life 
and avidity towards their antigens (reviewed here [40]). 
In this study we have engineered a panel of TEM1-
specific, fully-human, bivalent antibody-like reagents by 
fusing scFv78 with different domain components from 
the human immunoglobulin G1 (IgG1) Fc. We evaluated 
the affinities and stabilities of scFv78 and its derivatives 
and characterized their pharmacokinetic (PK) profiles in 
naïve and TEM1-positive graft bearing animals. Through 
these studies, we identified one construct, 78Fc, as being 
a strong candidate for immuno-imaging applications. 
In two preclinical models where mouse TEM1 is either 
spontaneously upregulated or human TEM1 is expressed 
in tumor vascular xenografts, we show that in vivo NIR 
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optical imaging using fluorochrome-labeled 78Fc can 
distinguish high-TEM1 expressing tumor grafts from 
normal organs. These findings support further clinical 
evaluation of 78Fc as an optical imaging agent in cancer 
patients. 
RESULT
Development and purification of oligomeric 
scFv78 -Fc fusion proteins 
Since the practical utility of many scFvs are often 
limited due to their small size, structural instability 
due to relatively weak variable domain interactions, 
and monovalency [1], we sought to construct novel 
oligomerised scFv78 variants more suitable for therapeutic 
and prognostic (theranostic) applications. To achieve 
this goal, we designed four multivalent scFv-Fc fusion 
proteins: 78F(ab`)2, 78CH2, scFv78-minibody (78mb), 
and scFv78-Fc (78Fc) (Fig 1A). While 78F(ab`)2 was 
generated by linking two scFv78 together via the IgG1 
core hinge region (CPPCP) , the other three variants 
were constructed by fusing different Fc regions to the 
C-terminal of scFv78. The calculated molecular weight of 
bivalent molecules of 78F(ab`)2, 78CH2, 78mb, and 78Fc 
are 65kDa, 90kDa, 90kDa, and 120kDa, respectively. A 
HA tag was added to the N terminus of the proteins for 
easy purification and detection, and upstream addition 
of the signal peptide from Ig KappaV enabled the fusion 
proteins to be secreted and easily purified from the media 
of the host 293T expression cells (sup Fig 1). Fusion 
proteins were purified by incubating the conditioned 
culture media with anti-HA affinity matrix beads. For 
all fusion proteins, we were able to purify 0.5-1mg/L 
protein at a purity >90%. Since the size exclusion HPLC 
(SE-HPLC) analysis of the purified proteins revealed 
additional peaks, suggesting the presence of aggregates/
multimers of the proteins (Fig 1B), we further analyzed 
the quarternary status of the proteins by polyacrylamide 
gel electrophoresis. Under reducing conditions, the 
migration of all scFv derivatives appeared consistent with 
their calculated molecular weights (Fig 1C). Under non-
Fig.1: Development, purification, and characterization of scFc78 fusion proteins. A, Schematic representation of the domain 
organization and the predicted molecular weights and valencies of scFv78 and the four scFv78 fusion derivatives. B, SEC analyses of 
affinity purified scFv78 and the four scFv78 fusion derivatives. C, multivalent status of scFv78 and the four scFv78 fusion derivatives by 
Western blot analysis with anti-HA antibody. R: reducing conditions, N: non-reducing conditions. * monomer, ** dimer, **** multimer.
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reducing conditions, while scFv78 remained monovalent, 
we observed apparent oligomerisation of the fusion 
proteins: for 78Fc and 78F(ab`)2, the majority of protein 
appeared dimeric; for 78CH2, the majority (>90%) of 
protein migrated with an apparent mass consistent with a 
tetramer; and for 78mb, about 40% of the protein remained 
monomeric. 
scFc78-Fc fusion proteins have higher avidity to 
TEM1 than scFv78
It is well established that increases in valency 
can improve the avidity of an antibody. To measure the 
avidities of scFv78 and its derivatives under conditions 
that are more relevant to in vivo settings, we established a 
live-cell ELISA assay to measure the binding of the fusion 
proteins to cell-surface TEM1. Briefly, we first modified 
Mile-Sven1 (MS1), a TEM1-negative endothelial cell 
line, to express human TEM1 at a moderate level, with 
the saturated maximal binding capacity (Bmax) of ~4 × 10
5 
per cell. Different concentrations of scFv78 derivatives 
were then incubated with either control or TEM1 positive 
MS1 cells. Following washing, remaining molecules 
bound to the live cells at each concentration were detected 
by ELISA. Specific binding was observed when the 
concentration of fusion protein was as low as 0.1 nM, and 
non-specific binding was not observed below 10 nM (Fig 
2A). While all samples tested have comparable Bmax, the 
fusion proteins all have lower apparent Kd values than 
scFv78, consistent with higher oligomeric avidities to 
TEM1 (Fig 2B). However, the apparent oligomerisation 
of 78CH2 does not translate into the expected avidity gain, 
suggesting that this species may have steric or structural 
issues. Among all antibodies tested, 78Fc demonstrated 
the lowest Kd value in sub-nanomolar range, which was 
~15-fold lower than that of scFv78 (Fig 2B). 
The stability and pharmacokinetic profiles of 
scFv78 fusion proteins 
Good biophysical stability and appropriate serum 
half-life are generally considered important prerequisites 
for antibodies or antibody products destined for clinical 
applications. To evaluate the stability of the scFv78 fusion 
proteins, we first measured their thermal stability by 
incubating the purified proteins with SYBR orange under 
a temperature gradient from 20°C to 99°C. Following 
incubation, the samples were analyzed by differential 
scanning fluorimetry (DSF), an assay employed to 
estimate protein degradation/unfolding and aggregation. 
The thermostability curves revealed that the melting 
temperatures (Tm) of scFv78 and its derivatives were 
comparable (Fig 3A). 
Next, we tested the in vitro serum stability of scFv78 
fusion proteins by incubating the proteins in 100% human 
serum at 37C for up to 7 days. Samples were collected at 
different time points during incubation, and HA-agarose 
beads were used to capture the fusion proteins. Serum 
stabilities were measured by quantifying the amount of 
bead-bound recovered protein by western blot analysis. 
In the presence of serum at 37oC, recoverable levels of 
scFv78, 78F(ab`)2, 78CH2, and 78Fc remained relatively 
consistent throughout the 7-day incubation; yet, the 
amount of bead-bound 78mb decreased significantly after 
two days of incubation (Fig 3B). This apparent instability 
of 78mb may be a consequence of its heterogeneous 
composition (Fig 1C). These observations suggest that, 
with the exception of 78mb, the scFv78 fusions possess 
sufficient physicochemical stability to make them 
attractive candidates for in vivo applications. 
Finally, we conducted in vivo pharmacokinetic 
studies to determine the blood clearance rates of scFv78 
fusion proteins. scFv78 and its fusion proteins were first 
radiolabeled with iodine-125 (125I). When injected into 
Fig.2: scFv78 fusion proteins demonstrate higher 
avidity to cell-surface TEM1. A, The dose-dependent 
binding curves of scFv78 and its derivatives. Cell-surface 
binding activity in control (MS1) or TEM1-expressing cells 
(MS1-TEM1) was measured by a live cell-based ELISA assay. 
TEM1-specific binding was calculated as the difference between 
binding to the control and TEM1-expressing protein. The control 
anti-TEM1 IgG is a biotinylated humanized mouse IgG1. B, A 
summary of the calculated Kd and Bmax of the scFv78 and scFv78 
derivatives. Anti-HA HRP was used as the secondary antibody 
in ELISA for all proteins except for the control anti-TEM1 
IgG which required strepavidin-HRP. * indicates the different 
secondary antibody used.
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naïve nu/nu mice, serum concentrations of these 125I–
labeled Fc fusion proteins decreased in a typical biphasic 
manner (Fig 3C). While scFv78 was rapidly eliminated 
from circulation, presumably via glomerular clearance, 
scFv78-derived fusion proteins were cleared from plasma 
much slower (fast-phase t1/2 of scFv78 and 78Fc are 0.04 
h and 0.31 h, respectively). Importantly, the slow-phase 
half-life of 78Fc is about 5.1 h, long enough to serve as 
an imaging tracer but short enough to avoid antibody-
retention-associated imaging background as seen with 
many full-length immunoglobulins. 
Codon-optimization, scale-up production and 
purification of the 78Fc fusion protein 
The observation that 78Fc displays encouraging in 
vitro thermal and serum stability behavior, in addition to 
possessing the highest avidity to TEM1 and a favorable 
murine PK profile, prompted us to investigate further the 
suitability of 78Fc for imaging applications by extending 
the study into preclinical mouse models. As a first step, 
we sought to improve the HEK cell expression yield 
and purification efficiency of 78Fc. We first improved 
the Homo sapiens Codon Adaptation Index (CAI) score 
of the 78Fc coding sequence to 0.96 (GeneOptimizer; 
Life Technologies). Subsequently, cis-acting sites (such 
as splice sites, RNA instability motifs, TATA box, GC-
hi and AT-hi regions, ribosomal entry sites) that could 
potentially inhibit protein expression were removed 
wherever possible. Finally, we adjusted the GC content 
to 63% to prolong mRNA half-life. These measures 
were sufficient to increase the yield of 78Fc from 0.5-1 
mg/L for the un-optimized gene, to 15-20 mg/L for the 
optimized gene expressed in HEK 293 Freestyle cells. 
We next sought to compare the purification capture 
efficiencies of anti-HA and Protein G matrices. 78Fc 
protein was first enriched with anti-HA agarose or Protein 
G, and the purified proteins were then subjected to size 
exclusion chromatography (SEC) prior to concentration of 
peak fractions (Fig 4A). The yields and purities of the final 
concentrated proteins were compared by SDS-PAGE using 
Western blot analysis and Coomassie dye staining (Fig 
4B, C). The results indicated that both affinity approaches 
were equally effective for purification with final purities 
exceeding 95%. Since purification using Protein-G is 
more cost-effective, we decided to use Protein-G capture 
combined with SEC to purify large quantities of 78Fc for 
in vivo testing.
Fig.3: The stability and pharmacokinetic profiles of scFv78 and its derivatives. A, Thermal stability curves of the antibody 
variants. Differential scanning fluorimetry was used to measure protein aggregation and degradation. B, Serum stability assay of scFv78 
and its derivatives. Purified antibody variants were incubated with 100% human serum for up to 7 days at 37°C. Samples taken at different 
time points were then analyzed by Western blot with anti-HA antibody. C, Pharmacokinetics of 125I-labeled anti-TEM1 variants in naïve nu/
nu mice. The half-lives (fast and slow, in hours) deduced from the study is underneath.
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78Fc biodistribution in vivo
Since scFv78 binds to both human and mouse 
TEM1 [37], we reasoned that mouse would be a valid 
preclinical model species for evaluating the tissue 
uptake and biodistribution of 78Fc. To characterize the 
tissue uptake and biodistribution of 78Fc in naïve mice, 
we first radiolabeled 78Fc and scFv78 with 125I. While 
the affinity of scFv78 to TEM1 decreased significantly 
upon conjugation (Fig 5A), the apparent affinity of 
radiolabeled 78Fc was still in the nanomolar range, only 
slightly lower than that of its unlabeled counterpart (Fig 
5B). The radiolabeled 78Fc was injected into naive mice 
and samples from multiple organs, including full blood, 
thyroid gland, heart, lung, kidney, spleen, liver, brain, 
uterus and ovary, were collected at different time points. 
The quantity of 78Fc protein present in the various tissues 
was assumed to correlate with the measured radioactivity. 
While there was an acute increase of measurable 
radioactivity following the 78Fc injection, the signals 
observed in normal mouse organs were seen to decrease 
rapidly with time, consistent with the absence of target-
mediated retention and reflecting the low detectable levels 
of TEM1 mRNA in these tissues (Fig 5D). Interestingly, 
one exception was the uterus where apparent retention/
accumulation of label appeared to correlate with a modest 
level of mouse TEM1 mRNA. It is worth noting that while 
kidney and liver are considered major clearance routes 
for scFv-Fcs, we did not detect any signal enrichment in 
these two organs. In tumor-bearing animals, we observed 
that 78Fc was not retained in normal tissues but was 
clearly enriched in TEM1-expressing tumors (Sup Fig 2). 
The observation that low levels of tracer accumulation 
occurred in the thyroid (Fig 5C), a phenomenon which we 
have observed previously [38, 39], can be attributed to the 
dehalogenation of the 125I –labeled 78Fc. Taken together, 
this data suggests that off-target or non-specific binding 
of 78Fc is unlikely to be a confounding factor for in vivo 
imaging.
78Fc as a tracer for optical imaging in murine 
TEM1-expressing lung tumor models
As a rapidly developing technology, optical imaging 
is becoming a promising diagnostic modality in cancer 
management. To evaluate 78Fc as an optical imaging 
tool, we first generated 78Fc-fluorochrome conjugates via 
two different coupling methods: N-hydroxysuccinimide 
(NHS)-esterification, and thiol (-SH, sulfhydryl) reactive 
maleimide chemistry. We chose VivoTag-S750 as the 
conjugating fluorochrome because the near infrared 
wavelength is ideal for both in vitro and in vivo biological 
imaging applications. In addition, with the fluorescence 
tomography (FMT) imaging systems, VivoTag-S750 can 
also provide quantitative, three-dimensional information 
of in vivo target tissues. While the fluorochrome-78Fc 
conjugate prepared with NHS chemistry effectively 
ablated the ability of 78Fc to bind to TEM1 (Fig 6A), 
the impact of maleimide coupling was far less dramatic, 
resulting in only a 3-fold reduction in apparent affinity 
for this conjugate (hereafter designated as 78Fc750) as 
compared to the underivatised 78Fc.
Next, we tested 78Fc750 in a TC1 mouse lung 
xenograft tumor model. While TC1 is a mouse lung 
metastasis cell line that expresses very little TEM1, 
TC1 tumor engrafts have high TEM1 mRNA expression 
(Fig 6B). To establish the TC1 tumor model for optical 
imaging, we stably transfected parental TC1 cells with 
firefly luciferase and sorted the luciferase-positive 
population. The luciferase expression allowed us to track 
tumor location and growth via bioluminescent signal 
detection in live animal imaging. Luciferase-positive TC1 
cells (1 × 105) were inoculated subcutaneously at a single 
site on the flanks of nude mice (n=5). One week after the 
inoculation, successful engraftment of TC1 tumors was 
Fig.4: Comparison of two purification methods for 
scale-up production of 78Fc fusion protein after codon-
optimization. Scale up production of fusion protein 78Fc was 
performed after codon optimized by adapting codon bias of 
Homo sapiens genes with GeneOptimizer (Life technology). A, 
Elution profiles on SEC columns after affinity purification with 
anti-HA (left panel) or Protein G (right panel) methods. 78Fc 
protein elution fractions which were pooled (red arrowhead) 
are indicated with dotted-lines. B and C, Comparison of the 
purification efficiencies of anti-HA and Protein G methods by 
Western blot analysis (B) and Coomassie blue staining (C). A 
yield of 15-20 mg/L were achieved post optimization from 293 
Freestyle cells (Invitrogen) compare with 0.5-1mg/L before 
optimization with purity >95%.
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Fig.5: 78Fc demonstrates little off-target binding in major mouse organs in vivo. A, B Kd/Bmax binding studies of radiolabeled 
anti-TEM1 scFv78(A) and 78Fc(B). The avidity of 78Fc to TEM1 was not significantly affected by 125I labeling. C, Biodistribution profile 
of 125I-78Fc protein in naïve mice, showing no TEM1-specific accumulation in major organs. Left, % injected dose/gram in major organs; 
right, % injected dose/gram in thyroid. D, muTEM1 mRNA level in normal mouse organs determined by qPCR. TEM1 expression in liver 
was set as 1 (open bars). MS1 and 2H11 (dark bars) are used as negative and positive controls.
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confirmed by bioluminescent imaging and the animals 
were then injected with 78Fc750 intravenously into the 
retro-orbital complexes. Near infrared optical images were 
acquired from 10 minutes up to 3 days post-injection of 
the tracer. Encouragingly, these TC1 tumors containing 
elevated levels of TEM1 mRNA were easily distinguished 
from surrounding normal tissues by NIR optical imaging 
using the 78Fc750 conjugate (Fig 6C). However, it should 
be noted that significant NIR signals were observed in 
the liver and kidneys of these tumor-bearing animals 
(Sup Fig 3). Since we did not find any enrichment of the 
125I-labeled 78Fc in the liver or kidney from the preceding 
biodistribution study, we attribute this apparent staining 
to the known instability of plasma accessible maleimide 
linkages [41] and to probable maleimide exchange 
reactions between78Fc750 and plasma components that 
direct the accumulation of the liberated Vivotag-S750 
to the key sites of excretion and metabolism. Similar 
phenomena have been described elsewhere [42, 43].
In order to confirm the above findings we 
established an alternative TC1 lung metastasis mouse 
model by inoculating the luciferase-positive TC1 cells 
intravenously into nude mice. The TC1-derived metastatic 
lesions formed seven days after cell inoculation and were 
confirmed by bioluminescent imaging. The TEM1 mRNA 
expression in TC1 lung metastasis lesions was higher than 
in the surrounding lung tissue (Fig 6D). In this model, 
NIR optical imaging with 78Fc750 was able to clearly 
Fig.6: 78Fc as an NIR optical imaging tracer in a murine TEM1-expressing lung cancer xenograft model. A, Live cell 
ELISA analysis of 78Fc labeled with Vivotag750 via either maleimide (red) or NHS (green) linkage. Blue indicates the binding activity of 
unlabeled 78Fc. B, TC1-derived subcutaneous tumor grafts express high level of muTEM1. 104 TC1 cells were injected subcutaneously 
into B6 mice and tumors were harvested at the indicated time (up to 6 wks). muTEM1 mRNA levels in tumor and parental cells were 
measured by qRT-PCR, and 2H11 and MS1 cells were used as positive and negative controls, respectively. C, in vivo bioluminescence 
imaging (BLI) and 78Fc750-based live NIR optical imaging in a TC1 subcutaneous tumor model (n=5). 78Fc750 was given via retro orbital 
injection (5 mg/kg in 100 uL) and a longitudinal study of NIR imaging was performed up to 3 days post injection (n=5). Green circle, 
muTEM1+ positive tumor. 1. heart; 2.brain; 3. liver; 4. lung; 5. spleen; 6. kidney; 7. small intestine; 8. bladder; 9. ovary; 10. uterus; 11. 
thyroid; 12. TC1 sc. xenograft. Residual tracer was observed at the injection site (retro-orbital complexes). D, TC1 lung metastatic lesions 
express higher levels of muTEM1 than normal tissue in the lung. E, in vivo bioluminescence imaging (BLI) and 78Fc750-based live NIR 
optical imaging in a TC1 lung metastasis model. 78Fc750 was given via retro orbital injection (5 mg/kg in 100 uL) and a longitudinal study 
of NIR imaging was performed at 3 days post injection (n=5). From left: ventral view of mouse BLI showing TC1 lung metastasis at day0; 
live animal NIR at day2 p.i. of 78Fc750; ventral view at day3 p.i. (postmortem) of same animal with liver and kidneys removed to show 
lung signal; all harvested organs including liver and kidneys; close up view of the lung. Green box, muTEM1+ positive lung tumor. 1. heart; 
2.brain; 3. liver; 4. lung; 5. spleen; 6. kidney; 7. small intestine; 8. bladder; 9. ovary; 10. uterus. 
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distinguish the TC1-derived lung lesions from surrounding 
healthy tissues (Fig 6E). 
78Fc as a tracer for optical imaging in human 
TEM1-expressing tumor vascular model
Next, we sought to evaluate the utility of 78Fc750 
for imaging the human TEM1-expressing tumor 
vasculature using a xenograft model we established 
previously [35, 36]. In this model, luciferase-expressing 
control MS1 cells (MS1) or human TEM1-positive MS1 
cells (MS1-hTEM1) were injected into opposite flanks of 
the same nude mice to grow control or TEM1-expressing 
tumor vascular grafts. Since mouse TEM1 expression 
remains low in these huTEM1-expressing tumor grafts 
(Fig 7A, B), we reasoned that this model could be used 
to evaluate the performance of 78Fc750 in detecting 
hTEM1-expressing grafts with NIR optical imaging. One 
week after grafting, the control and hTEM1-expressing 
MS1 vascular grafts were first assessed by bioluminescent 
imaging (BLI) (Fig 7C), before injecting 78Fc750 tracer 
for longitudinal NIR optical imaging. In common with 
the above biodistribution study in naive mice, the infrared 
signal in normal healthy organs, such as the heart, lung, or 
hTEM1-negative graft, was quickly cleared and became 
negligible within one day after tracer injection. In contrast, 
we detected intense and long-lasting fluorescence in 
hTEM1-positive grafts (Fig 7C). 
Beyond 2-dimensional (2D) planar BLI, recent 
advancements include the ability to acquire 3-dimensional 
(3D) diffuse luminescence tomographic images (3D 
DLIT). To further confirm the specific localization of 
78Fc to hTEM1-positive grafts, we conducted three-
dimensional imaging with DLIT (bioluminescent source 
reconstruction for spatial information of TEM1+ and 
Fig.7: 78Fc as an NIR optical imaging tracer in the human TEM1-expressing tumor vascular model. Human (A) and 
mouse TEM1 mRNA (B) expression in control and hTEM1 expressing tumor grafts. TEM1 mRNA levels were evaluated with qRT-
PCR. TEM1 expression in normal human or murine cervix was normalized to 1. 107 MS1-huTEM1 or control MS1 cells were injected 
subcutaneously into nude mice on the left or right flanks, respectively (n=3), and tumor grafts were harvested after the indicated time 
(2-3 weeks). huTEM1-positive tumor grafts express muTEM1 at similar levels to that of control tumor grafts. C, in vivo bioluminescence 
imaging (BLI) and 78Fc750- or IgG-750-based live NIR optical imaging in huTEM1-positive and control tumor grafts (n=3 per group). 
Green circle, MS1-TEM1 tumor; yellow circle, MS1 control tumor. D (Also in Sup videos), 78Fc750 BLI and NIR tomographic imaging 
in mice grafted with MS1-huTEM1 (lower) and MS1 (upper) in nude mice. Bioluminescent signals overlap with infrared signals only in 
the huTEM1-positive tumors. From left, picture (area inside the purple square is used for 3D dual modality imaging to regenerate mice 
surface), 3D reconstructions of bioluminescence (DLIT) and NIR fluorescence (FLIT); superimposed DLIT with FLIT. n=5.
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control engrafts) and FLIT (NIR fluorescence source 
reconstruction for spatial information of 78Fc750 tracer), 
and co-registration of the DLIT and FLIT voxels. We 
found that the bioluminescent and NIR fluorescence 
signals overlapped only at the site of hTEM1-positive 
grafts (Fig 7D, supplementary videos). Similar to the TC1 
models, fluorescence was observed in the livers of these 
mice (Sup Fig 4). These observations demonstrated that 
78Fc750 was specifically enriched in hTEM1-positive 
tissues. 
DISCUSSION
Antibodies now represent an established class of 
therapeutic reagents capable of inhibiting tumor growth 
and inflammatory disease progression in the clinic, with 
new registrations growing year on year. Increasingly 
however, antibodies are also being recruited as immune-
modulating agents, vehicles for targeted delivery, and 
as imaging agents for detecting and staging tumors, 
and for monitoring treatment response. In recent years, 
indium-111 satumomab pendetide (CYT-103), technetium-
99m nofetumomab merpentan (Verluma), technetium-99m 
arcitumomab (IMMU-4), indium-111 pentetreotide, and 
indium-111 capromab pendetide have been approved by 
the FDA as imaging agents for single-photon emission 
computed tomography (SPECT) in various cancers [2]. 
In addition, the radiolabelled derivatives of a growing 
number of therapeutic mAbs, including anti-CD44v6 
(U36) [44], anti-cMet (DN30) [45], anti-carbonic 
anhydrase IX (G250) [46-48], anti-fibronectin (L19-
SIP)[49], anti-IGF-1R (R1507) [50], anti-PSMA (J591 
and 7E11) [51, 52], anti-CD105 (TCR105) [53], anti-
EGFR (cetuximab) [54, 55], anti-CD20 (inbritumumab 
tiuxetan, rituximab)[56, 57], anti-VEGF (bevacizumab) 
[58, 59], and anti-HER2 (trastuzumab) [60-62] have been 
intensively evaluated in preclinical and clinical immuno-
PET studies. 
Although immuno-imaging with mAbs has met with 
some success [36], the large size of intact immunoglobulins 
effectively restricts their renal clearance which, together 
with Fc-recycling mechanisms, often results in prolonged 
circulating half-lives and a background of radioactivity 
that can persist for time frames that are incompatible 
with short duration high contrast imaging of specific 
target tissues. To reduce the half-life of circulating 
antibodies, extensive efforts have been directed towards 
developing antibody-based reagents with fewer domains 
and reduced size [63, 64]. The scFv minimal binding 
unit has featured heavily as a building block in such 
strategies (reviewed in [65]). Whereas scFvs themselves 
are considered poor reagents for imaging purposes, due 
mainly to a combination of rapid clearance and limited 
monovalent affinity, significantly better performance 
has been reported for several derivative scFv formats 
including scFv monomers conjugated to PEG or albumin, 
scFv dimers (diabodies), scFv-CH3 dimers (minibodies) 
and scFv-Fc dimers. One established strategy for domain 
reduction, and the subject of this work, is the design and 
construction of Fc-fusion proteins that comprise the Fc 
domain of an immunoglobulin and a (poly)peptide that 
possesses high affinity for the antigen of interest [66]. 
Such artificial constructs generally have reduced size 
and physicochemical and/or metabolic stability when 
compared alongside a native soluble immunoglobulin. 
Accelerated clearance for such molecules, although 
not expected per se, may arise from a combination of 
moderately improved renal clearance and/or degradative 
mechanisms, both endosomal and plasma-driven, which 
are dependent on the nature of the individual fusion. Fc-
fusion proteins with such properties may display higher 
blood clearance rates and have improved utility as imaging 
reagents. Though TEM1 is a well-validated tumor vascular 
marker and a promising theranostic target, currently there 
is only one chimeric, hTEM1-specific mAb undergoing 
clinical trials in patients with multiple types of cancer. To 
maximize the translational potential of TEM1, we have 
identified a potent TEM1-specific scFv, scFv78, arising 
from yeast display and FACS-based screening [37], and 
have explored the contribution of four different valency-
enhancing IgG1 Fc domain fusion arrangements to 
stability, avidity and pharmacokinetics.
For an antibody to perform well in imaging 
applications, it has to fulfill many criteria. Principally, it 
needs to maintain its avidity to the antigen after labeling. 
Here we observed that, unlike scFv78, which totally lost its 
binding to TEM1 upon radiolabeling, 78Fc retained high 
affinity binding following both radio- and fluorochrome- 
labeling. Additionally, an antibody needs to have a 
favorable PK clearance profile for imaging applications. 
Although murine PK data of antibody-related molecules 
is considered unreliable for extrapolating clearance rates 
to humans [67], the blood clearance rate of around 5 
hours for 78Fc in mice observed in our study, suggests 
that it may be possible for patients to be imaged within 24 
hours following the tracer injection. Finally, to minimize 
potential off-target toxicity and masking, an antibody 
reagent must show minimal retention in non-target 
tissues. The evaluation of this criterion is challenging in 
commonly used preclinical models as many antibodies 
recognize only their cognate human antigens. In our case, 
since scFv78 recognizes both human and mouse TEM1, 
we reasoned that a mouse model would be relevant and 
informative in evaluating the bio-distribution and imaging 
performance of 78Fc. In biodistribution studies, 125I-78Fc 
demonstrated negligible uptake by critical tissues such as 
heart, lung, kidney, liver, and brain, and this was also the 
case for NIR imaging with 78Fc750. The observed non-
specific signals in liver and kidney were most likely due 
to liberation and metabolism of the tracer, which could 
potentially be addressed using more optimal conjugation 
and linker chemistries. This finding is consistent with the 
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fact that most adult normal tissues express very low level 
of TEM1 [68], and it also suggested that 78Fc has very 
little off-target binding that can interfere with its imaging 
applications. 
To further evaluate 78Fc as an imaging tool, we 
tested in two different mouse models: TC1 lung metastasis 
model, in which TC1 tumor grafts have high expression 
of mouse TEM1; and hTEM1 expressing tumor vascular 
model, in which human TEM1-expressing endothelia cells 
formed hTEM1 expressing tumor vasculature. In both 
models, there was only negligible amount of signals in 
normal mouse organs like heart, lung and brain; however, 
in TEM1-positive grafts, we observed strong and long-
lasting near infrared signals. Therefore, it is strongly 
suggested that one of the scFv-78 based fusion protein 
we designed here may have a great potential as an optical 
imaging tool for clinical uses. One should note that unlike 
the biodistribution study with 125I-labeled 78Fc, where 
no normal organ showed any sign of antibody retention, 
our optical imaging studies revealed strong fluorescent 
signals in liver and kidney. This signal most likely reflects 
the known instability of plasma accessible maleimide 
linkages and maleimide exchange between 78Fc750 and 
plasma components, thusleading to the accumulation 
of the liberated fluorochrome at key sites of excretion 
and metabolism. In a previous study with a HER2/Neu 
antibody, maleimide-conjugated linkers were shown to 
readily exchange with reactive thiols on albumin, free 
cysteine and glutathione, with the local charge context 
of the cysteine conjugation site also influencing the 
stability of the succinimide ring [41]. Similar observations 
of apparent liver and kidney localization have been 
reported for other optical imaging tracer conjugates, for 
example the commercial product Transferrin-Vivo750 
(Perkin Elmer) and related conjugates [42, 43]. Thus, 
the chemical and structural dynamics of the conjugation 
site can influence antibody conjugate performance by 
modulating the stability of the antibody-linker bond, and 
contributing to non-specific background fluorescence in 
whole-body imaging applications. Further studies using 
conjugates stabilized by alternative chemistries and 
fluorochromes with improved free clearance profiles are 
clearly warranted.. 
NIR imaging has generally been considered practical 
only for tumors close to the body surface due to signal 
penetration limitations. However, recent technological 
advances are now challenging this perception by extending 
the utility of the approach to the imaging of internal organs 
in both pre-clinical and clinical settings [69-74]. As of 
June 2014, NIR imaging features in 14 clinical trials in 
intraoperative or endoscopic settings (www.clinicaltrials.
gov). Two trials, NCT02129933 and NCT02113202, are 
concerned with evaluating, respectively, Bevacizumab-
conjugated NIR tracers in patients with esophageal cancer 
and adenomatous polyposis.. Based on the encouraging 
results we have obtained using 78Fc-based NIR imaging 
reagents in pre-clinical models, further development 
activities are underway in order to maximize the 
translational potential of this antibody. 
In summary, optical imaging is emerging as an 
important alternative to established radio-imaging 
technology. Immuno-optical imaging can provide accurate 
and specific information regarding the target tissue without 
invasive treatment or exposing the patient to radioactivity. 
It can also provide real time, spatial information regarding 
biomarker expression, which can help physicians to make 
clinical decisions during operations and guide treatment. 
In the current study we have demonstrated encouraging 
preliminary optical imaging results for a novel anti-
TEM1 Fc-fusion reagent in a preclinical setting. Further 
optimization of the fluorochrome and conjugation 
chemistry is clearly warranted. Additionally, given that 
78Fc can distinguish both human and murine TEM1-
positive lesions from control lesions and surrounding 
normal tissues, our study also paves the way for 
developing 78Fc as a tracer for TEM1-targeted immuno-
PET in both preclinical and clinical applications.
METHODS
Reagents and antibodies 
Goat pAb to HA tag (HRP) antibody was from 
Abcam. Streptavidin HRP was from BD Biosciences. 
Biotinylated MORAb004 (humanized mouse IgG1 
recognize human but not mouse TEM1) was produced 
by Morphotek Inc. pcDNA 3.3/3.4 vector, FreeStyle™ 
293 Expression medium, Freestyle MAX reagent and 
OPTI PRO serum free medium were from Invitrogen. 
Anti-HA affinity matrix and HA peptide were from 
Roche. Silverquest staining kit was from Invitrogen. 
Sureblue TMB microwell peroxidase substrate and TMB 
stop solution were from KPL. HA Tag IP/Co-IP Kit was 
from Pierce Thermo Scientific. VivoTag-S 750-MAL 
and VivoTag-S 750 fluorochrome is from Perkin Elmer. 
Taqman qRT-PCR primers are from Applied Biosystems. 
Bicistronic lentiviral vector plasmid pKH-GFP-
pUbi-EmeGFP for fusion protein expression was based 
on pHR-SIN backbone [75]. The Fc region used in the 
constructs is derived from locus AJ294730. The scFv78 or 
Fc-fusion cDNA was cloned into sites of lentiviral vector 
plasmid as MluI-NotI PCR fragments to replace the GFP 
fragment and to generate pKH-scFv78, 78Fc, 78F(ab)2, 
78CH2, and 78mb respectively. The corresponding 
lentivirus was generated by calcium phosphate-mediated 
transient transfection of the antibody constructs together 
with the plasmids encoding the vesicular stomatitis virus 
G envelope gag-pol genes and pHRSIN-TEM1 into HEK-
293T cells. Conditioned media containing virus were 
harvested 24 and 48 hours post-transfection, filtered with 
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0.45 μm filters, and frozen at -80 °C for further use.
Cell lines
MILE SVEN 1 (ATCC) mouse endothelial cell 
line engineered to express DsRed and firefly luciferase, 
denoted MS1, has been described previously [35, 36]. 
MS1 was used for subsequent generation of the MS1-
TEM1 cell line that expresses human TEM1 (hTEM1) 
and EmGFP, in addition to DsRed and fLuc [35, 36]. 
2H11 murine endothelial cell line was used as muTEM1-
positive control (ATCC). TC1, a C57BL/6 mouse lung 
adenocarcinoma cell line transformed with HPV-16 E6 
and E7, was a generous gift from Dr Yvonne Patterson 
(University of Pennsylvania). The TC1 cell line 
engineered to express firefly luciferase fLuc, denoted 
TC1, was used in this study. MS1, MS1-TEM1, 2H11 and 
TC1 cells were cultured in RPMI1640 medium (Corning 
Cellgro, USA) containing 10% fetal bovine serum (FBS), 
100 I.U/mL penicillin, and 100 μg/mL streptomycin. Cells 
were incubated at 37°C in a humidified atmosphere of 5 
% CO2. 293-F cells were cultured in Gibco® FreeStyle™ 
293 Expression Medium (Invitrogen) in a shaker flask and 
incubated in a 37°C incubator containing a humidified 
atmosphere of 8% CO2 in air on an orbital shaker platform 
rotating at 125rpm.
Transfection and protein purification
Transfection of FreeStyle™ 293 cells was done 
according to the manufacturer’s instruction. The culture 
supernatants were harvested at 72h post transfection and 
filtered through 0.45μm filter unit before purification. 
The supernatants were concentrated with 10k MWCO 
centrifugal filters (Millipore) and dialyzed with PBS 
before further purification. Small-scale protein purification 
was performed according to the manufacturer’s protocol 
for anti-HA affinity matrix (Roche). Briefly, samples were 
incubated with Anti-HA affinity matrix and following 
three washes, specifically-bound proteins were eluted by 
HA peptide (Roche) in elution buffer and then dialyzed 
with PBS three times. The purity of each protein was 
analyzed using coomassie blue staining, Silverquest 
staining (Invitrogen) and SEC analysis.
Codon optimization and scale up production and 
purification
The codon usage was analyzed with 
GeneOptimizer® (Life Technologies) and adapted to the 
codon bias of Homo sapiens genes. In addition, regions of 
very high (>80%) or very low (<30%) GC content were 
avoided where possible. During the optimization process, 
the following cis-acting sequence motifs were avoided: 
internal TATA-boxes, chi-sites and ribosomal entry sites; 
AT-rich or GC-rich sequence stretches; RNA instability 
motifs; repeat sequences and RNA secondary structures; 
splice donor and acceptor sites in higher eukaryotes. Post 
optimization, GC content was adjusted to prolong mRNA 
half-life [76]. Codon usage was adapted to the bias of 
Homo sapiens resulting in a CAI (codon adaptation index) 
value of 0.96. 
Scale up protein production was done using the 
codon-optimized sequence in the pcDNA3.3 vector 
according to the manufacturer’s protocols (Invitrogen). 
In brief, 6 days post-transfection, the supernatant was 
concentrated by tangential flow filtration before being 
applied onto anti-HA agarose or HiTrap Protein G HP 
for affinity enrichment. The binding buffer was 20 mM 
sodium phosphate and the elution buffer was 0.1 M 
Glycine (pH 2.4). All collection tubes contained 20% 1 
M Tris-HCl (pH8.0) to neutralize the eluate fractions. 
Enriched protein was further purified by SEC on a 
Sephacryl S200 column pre-equilibrated with PBS (pH 
7.5). Fractions containing the purified protein were 
pooled and dialyzed for 16 h against PBS (pH 7.5) before 
adjustment to 1mg/mL. Aliquots were stored at -80°C. 
Purity was determined as described above. Yield (mg/
Liter culture) was quantified by spectrophotometry with 
a Nanodrop 2000 instrument (Thermo Scientific) and 
coomassie staining alongside a known loading of BSA.
Western blot analysis and multivalent status assay 
of the antibody variants
Proteins were separated according to their molecular 
weight on 4-15% Mini-protean TGX precast gels (Bio-
Rad) and transferred onto Immobilon-P transfer membrane 
(Millipore). Membranes were blocked for 1 h in 5% dried 
milk in TBST at room temperature and probed overnight 
at 4°C with rotation in primary antibody anti-HA-HRP 
(Abcam, 1:5000 dilute). After 3 washes, the bands were 
visualized using a chemiluminescent substrate (GE 
Healthcare).
SEC analysis of purified fusion proteins
Recombinant antibody reagents including 78Fc, 
78F(ab`)2, 78CH2, 78mb, and scFv78 were analyzed 
via a Superdex 200 10/300 gel-filtration column (GE 
Healthcare). 10-25µg of antibody was diluted with PBS 
to a final volume of 250 μL. The samples were spanned 
at 20,000 g for 5min before injection. The sample was 
applied via a 500 μL loop at a flow rate of 0.5 mL/min 
using an AKTA FPLC system (GE Healthcare). The 
eluting protein was detected by UV absorbance at 280 
nm and the elution volumes were recorded for analysis. 
Column calibration with appropriate MW standards (Bio-
Rad) was performed prior to and following each run in 
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order to allow the estimation of antibody reagent MWs. 
Peak fractions were collected using the AKTA FPLC Frac-
950 collector for further analysis.
Radiolabeling and Immunoreactivity assays
Purified fusion proteins (50 µg) were radio-iodinated 
with ~18.5 MBq (0.5 mCi) of 125I-NaI (Perkin Elmer) 
in 0.01 N NaOH for 5 min using pre-coated iodination 
tubes (Thermo Scientific) as previously described [35]. 
Radiolabeled antibody was purified over a 2 mL desalting 
column (Thermo Scientific). Following trichloroacetic 
acid precipitation, radiolabeling efficiency was determined 
by radio-TLC.
Immunoreactivity was assayed as previously 
described [35]. Briefly, radio-iodinated proteins (5 nM 
− 0.016 nM) were incubated with an excess of MS1-
TEM1 cells for 1 h. The mixture was centrifuged, and 
the activity remaining in the supernatant was counted. 
A more sensitive assessment of specific binding was 
done by live-cell radioimmunoassay (RIA). Cells were 
grown to confluence on 1% gelatin-coated 96-strip well 
microplates (Corning Life Sciences). For the binding 
assay, monolayers of cells were incubated with increasing 
concentrations of 125I-labeled proteins in assay buffer (5% 
FBS in RPMI 1040) in quadruplicate at 4 °C for 4 h. At 
the end of incubation, cells were washed five times with 
ice-cold wash buffer (3% BSA/PBS). The cell-associated 
radioactivity was measured by a gamma (γ) counter 
(Wizard 2470, Perkin Elmer) and was normalized to the 
total number of cells, as counted by a hemocytometer. 
Non-specific binding (NSB) was calculated by subtracting 
the radiolabel bound to control MS1 cells from the total 
binding. The data from the live-cell RIA experiments 
were analyzed by Scatchard analysis using Prism 5.0 
(GraphPad) software to determine equilibrium binding 
constants and the number of functional binding sites. The 
apparent binding affinity, Kd, for specific binding was 
calculated using non-linear regression analysis of a one-
site binding hyperbola equation. Bmax is the maximum 
number of binding sites per cell at the asymptotic 
maximum; Kd and Bmax values are presented as the mean 
± SD of three or more independent experiments, and each 
independent experiment was performed in quadruplicate.
Blood pharmacokinetics (PK) and biodistribution 
studies
Naïve mice were administered 125I-labeled protein 
(0.185 MBq [5 μCi], 5 μg of protein, in 150 μL of saline) 
via the tail vein (0 h). Blood samples were collected 
at designated time points by retro-orbital bleed for 
assessment of blood activity levels. Blood activity levels 
were fitted to bi-exponential decay curves, and decay 
constants were calculated. Animals (n = 3–6 per group) 
were euthanized at 1, 2, 4, 24, 48, 72, and 144 h after 
injection. Organs and tumors were harvested and weighed, 
and the accumulated radioactivity was counted in a gamma 
counter. 
Live-cell ELISA-based direct binding assay
96-well plates were coated with 50 μL 2% gelatin 
(Sigma) at 37°C for 30 min. After discarding the gelatin, 
plates were washed with 200 μL PBS. MS1 and MS1-
TEM1 cells were seeded in plates (2×104 cells per well) 
and grown at 37°C overnight. Cells were incubated with 
11 doses (starting from 100 nM, 3 × serial dilution) 
of antibody reagents in cell culture media at 4°C for 2 
h. Plates were washed 3 times with 200 μL PBS and 
incubated with secondary antibody in cell culture media 
at 4°C for 1 h. For scFv78 fusion proteins, the secondary 
antibody was HA-HRP (Abcam, 1:1500 dilutions), for 
Biotinylated MORAb004, the secondary antibody was 
SA-HRP (Abcam, 1:1000 dilutions). Plates were washed 
with 200 μL PBS three times and then developed with 100 
μL Sureblue TMB microwell peroxidase substrate (KPL) 
for 10 min. 100 μl TMB stop solution (KPL) was added 
to each well and the A450 was measured in a plate reader 
(BioTek EL800). ELISA binding curves were analyzed 
using Prism5.0 (GraphPad) software to determine relative 
binding affinity constants (IC50). Data were fitted using 
the “non-linear four-parameter logistic sigmoidal dose-
response model”. The Kd value was then calculated from 
the IC50 value according to Cheng-Prusoff method [77]. Kd 
values are reported as the mean ± standard deviation (SD) 
of three independent experiments, and each experiment 
was performed in triplicate. 
Serum stability in vitro
500 ng of purified proteins (78Fc, scFv78, 78CH2, 
78mb, or 78F(ab`)2) were added to 250 µL of 100% human 
serum and incubated at 37°C with shaking. An aliquot 
(25 μL, 100ng protein) of the mixture was taken out at 
each time point (4h, 24h, 48h, 72h, 96h, 7d) and diluted 
to 800 μL with PBS, and the HA-tagged protein was 
captured using the HA Tag IP/Co-IP Kit (Pierce). Briefly, 
each sample was loaded onto the column followed by 
the addition of 20 μL of anti-HA agarose. Columns were 
incubated with gentle end-over-end mixing for 2 h at 4°C, 
then washed 3 times with 0.5 mL PBST and added to 25 
μL of 2× Non-Reducing Sample Buffer. The spin column/
tube assembly was heated at 100°C on a heating block for 
5 minutes and centrifuged for 10 seconds. The collected 
samples were electrophoresed in a 4-15% Mini-protean 




Thermofluor assays were performed to assess the 
thermal stabilities of purified proteins. The reaction mix 
contained 5 µL of 30x SYPRO®Orange dye (Invitrogen) 
and 45 µL of sample at 0.11 mg/mL in PBS pH 7.4. 10 
µL of the mix was dispensed in quadruplicate into a 384-
well PCR optical plate and was analyzed on a 7900HT 
real-time PCR System (Applied Biosystems) with a ramp 
rate of 0.5°C/min between 20°C and 99°C. Fluorescence 
changes in each well were measured, intensity increases 
plotted, and the inflection point of the slopes was used to 
calculate the thermostability (Tm).
RNA isolation and qRT-PCR
Total RNA was isolated from 50–100 mg of frozen 
organs or tumors with TRIzol reagent (Invitrogen). After 
treatment with RNase-free DNase (Invitrogen), RNA 
was reprecipitated, quantified by spectrophotometry and 
analyzed for RNA integrity by BioAnalyzer (Agilent). 
Total RNA was reverse transcribed using the Superscript 
First-Strand Synthesis Kit (Invitrogen) for RT-PCR under 
conditions described by the supplier. Quantitative RT-
PCR was performed with inventoried mouse or human 
tem1 probe (Applied Biosystems) with 18S probe as 
endogenous control. The expression of tem1 in normal 
organs was normalized using mouse liver or cervix as a 
calibrator. MS1, TC1 or 2H11 cell lysates were harvested 
and total mRNA extracted using Trizol, followed by 
DNaseI treatment and cDNA generation. Relative gene 
expression was calculated by the comparative CT method 
(2−ΔΔCT method). Error bars denote standard deviation 
(n=3) or as indicated.
Conjugation of 78Fc with Vivotag750
Conjugation of 78Fc or control human IgG 
(Genscript) with VivoTag-S 750 and VivoTag-S 
750MAL (Perkin Elmer) was performed according to 
the manufacturer’s instructions. Briefly, 1 mL of a 1 
mg/mL antibody solution in conjugation buffer (50mM 
carbonate/bicarbonate buffer, pH8.5) was mixed with 
30μL of VivoTag-S 750 at a concentration of 10mg/mL 
in Dimethylsulfoxide (Sigma) and then incubated at room 
temperature for 1 h. After dialysis in 1×PBS, the reaction 
mixture was filtered through a 0.2 μm syringe filter. 
Aliquots of labeled protein were stored at 4 °C in the dark 
until ready to analyze.
Murine TEM1-expressing models of TC1
Subcutaneous (s.c.) tumors with upregulated 
expression of endogenous murine TEM1 were established 
by s.c. injection of 4×104 TC1 cells into the right flank 
of nude mice. All animal experiments were conducted 
in compliance with Institutional Animal Care and Use 
Committee guidelines. Female athymic nu/nu mice (strain 
088 Nude-/-, 18 g, 4-6 weeks, Charles River Laboratories) 
were acclimatized at the Small Animal Imaging Facility 
(SAIF) vivarium for 1 week before tumors were implanted. 
Mice were provided with food and water ad libitum. These 
TC1 cells express firefly luciferase, enabling BLI imaging. 
Following resections at indicated time points, excised 
organs and tumors were analyzed for muTEM1 mRNA 
by quantitative RT-PCR. These mice will develop TC1-
induced s.c. tumors of approximately 5x5mm within 10 
days of cell inoculation and succumb in 5-6 weeks. At day 
10 after cell inoculation, 78Fc750 tracer (5 mg/kg) was 
injected intravenously (n=5) for longitudinal 2D planar 
NIR and BLI optical imaging. 
Lung metastasis tumors were established by 
intravenous injection of 1×105 luciferase expressing TC1 
cells. These mice will grow BLI visible lung tumors within 
7 days after cell inoculation and succumb in 3-4 weeks. 
Following resections at 2 wks post injection, excised lung 
and control organs were analyzed for muTEM1 mRNA by 
quantitative RT-PCR. At day 14, 78Fc750 tracer (5 mg/
kg) was injected intravenously (n=5) for longitudinal 2D 
planar NIR and BLI optical imaging.
Human TEM1-expressing tumor vascular model
Subcutaneous (s.c.) tumor vascular grafts expressing 
hTEM1 were established by s.c. injection of 2 x 107 
MS1-TEM1 or MS1 in each flank (for 2D study) or 
on the back for 3D tomography studies (upper: MS1; 
lower MS1-TEM1). Full details of the model has been 
described previously [36]. At day 14, 78Fc750 tracer (5 
mg/kg) or control IgG-750 were injected intravenously for 
longitudinal 2D planar NIR and BLI optical imaging (n=3 
per group). Mice bearing MS1-TEM1 and MS1 tumors on 
the back were suitable for studies using transillumination 
light sources and could therefore be used with dual 
modality tomography (DLIT and FLIT) (n=5).
In vivo 2D planar Bioluminescence Imaging (BLI) 
and Diffuse Light Imaging Tomography (DLIT)
Mice bearing engrafts expressing fLuc reporter 
(MS1 or TC1 cells) were anesthetized with 1-2% 
isoflurane/O2 and BLI was performed using the IVIS 
Spectrum small animal imaging system (Caliper). Briefly, 
D-Luciferin (150 mg/mL, Gold Biotechnology) was 
injected intraperitoneally and optical images were acquired 
15 min post-injection. Images were quantified with 
Living Image Version 3.0 software (Caliper). Quantitative 
bioluminescence imaging was performed as described 
elsewhere [78]. The mice bearing MS1-huTEM1 and MS1 
Oncotarget7008www.impactjournals.com/oncotarget
tumors on the back underwent 3D DLIT at day 14 post 
engraftment (n =3). A structured light image was acquired 
and followed by a sequential series of images using 20 
nm–wide filters centered on wavelengths from 560 to 
660 nm. Three-dimensional DLIT takes into account the 
source emission spectrum as well as the scattering and 
absorption of light in tissues and can thereby calculate the 
3D location and brightness of the luminescent source [79].
In vivo 2D planar NIR fluorescent Imaging and 
Fluorescence Imaging Tomography (FLIT)
Mice engrafted with MS1 or TC1 were also imaged 
with the Pearl Impulse small animal imager (LI-COR), an 
NIR imaging system designed for use with 700 nm and 
800 nm wavelengths. This system was used to measure 
the 78Fc750 signal at 800 nm in the longitudinal study 
after antibody–dye conjugate injections (1 min up to 10 
days post injection). Post mortem images were taken to 
visualize the organ distribution of the labeled antibody.
In addition, the mice bearing MS1-huTEM1 and 
MS1 tumors on the back underwent FLIT to determine 
geometry and to quantify the depth and intensity of 
fluorescent sources in 3D space (n=5). First we obtained 
a structured light image to reconstruct the surface 
topography and then fluorescent images (Ex: 745nm; Em: 
800nm) were obtained using multiple transillumination 
points and the same excitation and emission for 
tomographic mapping of source locations. Voxels were 
chosen for visualization. A generic mouse organ atlas was 
used to overlay the surface/source reconstruction, which 
allows the surface shape of the liver to be displayed. The 
liver voxels were later confirmed by post mortem 2D 
planar NIR of organs. 
In vivo Dual Modality Tomography (DLIT with 
FLIT)
The tomography source reconstruction and analyses 
were performed strictly according to the manufacturer’s 
instruction (Perkin Elmer). The mice bearing MS1-
huTEM1 and MS1 tumors on the back underwent, 
sequentially, FLIT followed by DLIT while maintaining 
their physical location/position on the imaging platform. 
The identical surface topographies from DLIT and FLIT 
enabled us to combine voxels from FLIT or DLIT for 
reconstructions. Such operations make it possible to 
directly visualize in vivo the co-localization of tumor 
cells (DLIT) with the 78Fc750 tracer (FLIT). Following 
resections, excised organs were placed in tissue cassettes 
and imaged under 2D planar NIR.
Statistical analysis 
Unpaired student’s t-test or two-way ANOVA 
statistical analyses were carried out using the SPSS and 
StatView software packages. A value of p<0.05 was 
considered statistically significant. 
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